Latest news with #Drug
Mint
2 days ago
- Business
- Mint
HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here
HDFC Mutual Fund has increased its stake in Glenmark Pharmaceuticals, breaching the 5 percent ownership threshold, as per the company's regulatory filing on June 18, 2025. The move comes even as Glenmark disclosed recent regulatory scrutiny of its U.S. manufacturing facility by the United States Food and Drug Administration (USFDA). According to the filing, HDFC Mutual Fund purchased an additional 3.57 lakh equity shares of Glenmark Pharma, raising its holding by 0.13 percent. Prior to the transaction, the fund house held 1.39 crore shares, or 4.94 percent of the company. Post acquisition, its total shareholding stands at 1.43 crore shares, which translates to a 5.07 percent stake in the pharmaceutical major. The stake increase is seen as a mark of confidence in the company's fundamentals and long-term growth potential, especially amid recent regulatory developments. As per the March 2025 shareholding pattern, Glenmark's promoters continue to hold a dominant 46.65 percent stake in the company. In parallel with the stake hike, Glenmark Pharmaceuticals also updated the stock exchanges about a recent Good Manufacturing Practice (GMP) inspection conducted by the USFDA at its Monroe, North Carolina facility in the U.S. The inspection, which spanned from June 9 to June 17, 2025, culminated in the issuance of a Form 483 with five observations. The company was quick to clarify that the observations were procedural in nature and did not pertain to data integrity—an issue that often raises red flags in the pharmaceutical industry. In its exchange communication, Glenmark stated, 'The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.' A Form 483 is typically issued when the FDA investigator identifies possible violations of the Food, Drug, and Cosmetic (FD&C) Act, but the absence of critical concerns such as data falsification is considered a relatively positive outcome. On the market front, Glenmark Pharma shares saw some volatility, falling by as much as 1.5 percent to touch a low of ₹ 1,634.55 on June 18. The stock is still around 11 percent below its 52-week high of ₹ 1,830.05, which it had touched in October 2025. However, it remains significantly above its 52-week low of ₹ 1,199.95, seen in June 2024. The recent price trajectory shows renewed investor interest, with the stock gaining 12.5 percent in June so far, following a 5.5 percent rise in May. This follows a choppy start to the year where the stock fell over 10 percent in April, surged 20.5 percent in March, and posted losses of 12 percent and 9.7 percent in February and January respectively. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Daily Record
3 days ago
- Health
- Daily Record
MSP demands action as Ayrshire suspected drugs death figures raise
Between January and March this year, 36 deaths were recorded in Ayrshire where drugs are suspected to have been involved. A MSP has demanded action after new statistics revealed an increase to the number of suspected drug -related deaths in Ayrshire. Figures published by the Scottish Government revealed that, between January and March this year, there were 36 deaths in the county where drugs are suspected to have been involved. It is the second-highest figure recorded in Ayrshire for any quarter since Police Scotland began compiling the figures in 2017. South Scotland MSP, Colin Smyth, has called for action to bolster support for drug rehabilitation and treatment following the release of the statistics. Across Scotland, 308 suspected drugs deaths were recorded in the first quarter of the year - a decrease of 12 on the same period in 2024. The quarterly figures are compiled by Police Scotland and are different to the annually complied figures by the National Records of Scotland. Police Scotland management information is used in the report to provide an indication of current trends in suspected drug deaths across the country. Commenting, Mr Smyth said: 'These tragic statistics show the human cost of over a decade of government failure to tackle Scotland's drugs crisis. 'For the first three months of the year, Ayrshire has recorded 36 drug deaths – and that is 36 too many. It is also the highest figure for three month period that we've seen in years. We must not forget that these numbers represent real people, with real families and friends who are mourning their loss. 'The fact is that there is no silver bullet to bring down drugs deaths – what we need is a joined up approach that includes properly supported rehabilitation and treatment services. 'Delaying action to tackle drug deaths has fatal consequences – it is time for the government to wake up to the tragedy continuing to unfold on its watch and act to save lives.' Health Secretary Neil Gray said: 'Every death is a tragedy and through our £250 million National Mission we are determined to continue our efforts to reduce harm and deaths. My condolences go to anyone who has lost a loved one. 'While these figures show a quarter-on-quarter rise in suspected drug deaths, they also note a year-on-year fall. We want every person experiencing harm to be able to access the support they need. 'We are taking a wide range of evidence-based measures including opening the UK's first Safer Drug Consumption Facility pilot, working towards drug-checking facilities and widening access to treatment, residential rehabilitation and life-saving naloxone.'
Yahoo
4 days ago
- Health
- Yahoo
Kraft Heinz to remove artificial colors from Jell-O and Kool Aid, among other brands, by 2027
Kraft Heinz (KHC) is getting rid of synthetic dyes across the remaining 10% of its US portfolio that contains them. That means changes are coming for beverage and dessert items like Crystal Light, Kool-Aid, Jell-O, and the marshmallow brand Jet Puffed. Kraft Heinz will remove the artificial colors and replace them with natural colors. If that is not possible, it plans to reinvent the items with new colors. Effective immediately on Tuesday, the company will not launch any new products that contain the food additives. "The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of Food, Drug & Cosmetic (FD&C) colors across the remainder of our portfolio," North America president Pedro Navio said in the release. The company removed artificial flavors, colors, and preservatives from Kraft Mac & Cheese in 2016. This announcement comes amid growing scrutiny of food additives. During the final days of former former President Joe Biden's term, the Food and Drug Administration (FDA) announced the ban of Red Dye No. 3 by 2027. In April, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said he wants "real and transformative" change by "getting the worst ingredients out' of food, according to a letter viewed by Yahoo Finance that summarized the HHS secretary's remarks to the Consumer Brands Association. By the time he leaves office, RFK Jr. wants to remove artificial coloring from the entire food supply. Per the list of ingredients, Kool-Aid Unsweetened Grape Powdered Drink Mix available on Walmart's website contains Red 40 and Blue 1. Another offering, Kool-Aid Unsweetened Cherry Powdered Soft Drink Mix, contains Blue 1. Strawberry Jell-O has "artificial flavor" listed under the title and includes Red 40 in the ingredients. This comes as Kraft Heinz, General Mills (GIS), and WK Kellogg (KLG) are facing multiple headwinds, including healthier eating trends, GLP-1s, and the impact of macro uncertainty in general, causing consumers to be extra intentional about discretionary snack purchases. Kraft Heinz's overall portfolio — ranging from Jell-O to Lunchables — saw its volume mix drop 5.6 percentage points in the quarter. Kellanova (K), which is behind brands like Cheez-Its and Pringles, saw its volume decline in North America. The company is in the process of being acquired by Mars. Brooke DiPalma is a senior reporter for Yahoo Finance. Follow her on X at @BrookeDiPalma or email her at bdipalma@ Click here for all of the latest retail stock news and events to better inform your investing strategy Sign in to access your portfolio
India.com
4 days ago
- Entertainment
- India.com
Shahid Kapoor Celebrates 9 Years Of Playing Tommy Singh In ‘Udta Punjab'
Mumbai: Bollywood actor Shahid Kapoor took a moment to reflect on one of the most transformative roles of his career as "Udta Punjab" completed nine years on Tuesday. The actor, who portrayed the wild and troubled rockstar Tommy Singh, shared a special post to celebrate the film and the impact the character had on his journey as a performer. Known for pushing boundaries, Shahid's portrayal of Tommy remains one of his most acclaimed and talked-about performances to date. Taking to Instagram, the 'Jab We Met' actor shared an image of his character and penned a heartfelt note, describing the role as 'another one of the flawed protagonists' he has always enjoyed portraying. View this post on Instagram A post shared by Shahid Kapoor (@shahidkapoor) The actor noted how such complex roles seem to have become more popular over time. Shahid also extended his gratitude to director Abhishek Chaubey, producers Anurag Kashyap, Vikramaditya Motwane, and Vikas Bahl, and the entire team for making the journey memorable. The 'Kabir Singh' actor wrote, '9 yrs. Another special character. Another one of the flawed protagonists that I always loved to play. They seem to be in fashion now. Thank you @abhishekchaubey, @anuragkashyap10, @motwayne, Vikas Bahl, and the entire team for making this journey so special. And of course. Drug's di maa d.' 'Udta Punjab,' the 2016 crime drama, was directed by Abhishek Chaubey and co-written with Sudip Sharma. The film was jointly produced by Shobha Kapoor, Ekta Kapoor, Sameer Nair, and Aman Gill under Balaji Motion Pictures, in collaboration with Anurag Kashyap, Vikas Bahl, and Vikramaditya Motwane of Phantom Films. Set against the backdrop of rampant drug abuse among the youth in Punjab, the story delved into the dark realities and underlying conspiracies surrounding the crisis. The film featured a powerful ensemble cast, including Shahid Kapoor, Alia Bhatt, Kareena Kapoor Khan, and Diljit Dosanjh. The crime drama, which received widespread criticism in Punjab, was released on 17 June 2016.
Yahoo
12-06-2025
- Business
- Yahoo
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades WALTHAM, Mass. & GENEVA, June 12, 2025--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA's decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity. Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world's countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use. About Uncomplicated Gonorrhea With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences. With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984. About Zoliflodacin Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial. About GARDP The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to For information about Innoviva Specialty Therapeutics, go to ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil. View source version on Contacts Media Innoviva Specialty TherapeuticsDavid +1.908.421.5971 GARDP Duncan Graham-Rowedgrahamrowe@ +44 7966 413623 Investors Argot Partnersinnoviva@ +1.212.600.1902 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
